Next Generation Sequencing of GATC Biotech AG Accredited by German DAkkS
|| Print ||
|Monday, 03 December 2012 10:00 (UTC + 1)|
GATC Biotech customers can expect highest quality standards for Next Generation Sequencing projects from official accreditation
Konstanz, Germany, December 3, 2012 / B3C newswire / – Being the first in Europe, the Next Generation Sequencing Laboratories of the Constance Genome and Diagnostics Centre has been accredited according to ISO 17025 from the national accreditation body for the Federal Republic of Germany (DAkks). The independent governmental institution has acknowledged the high quality standard of the sequencing service on technology platforms Illumina HiSeq and Roche GSFLX sequencing.
“As an accredited service provider we assure our customers the latest state-of-the-art standards in our methods, technologies and data quality at all times. This is especially important to our customers from the industry or diagnostics. A reliable and continuously high quality of the analysis service is of great importance to them. The accreditation allows all customers to compare the quality of service providers on the international sequencing market”, explains Dr. Marcus Benz, COO of GATC Biotech AG.
“While inspecting the laboratories, we met a very qualified and motivated team that has developed a high competency for the complex analysis. Apart from the staff and the excellent equipment, the LIMS system has to be highlighted. This in-house developed software system allows a wide monitoring of the processes and contributes especially to internal quality management”, says the DAkkS expert.
Since June 2012, the accreditation according to ISO 17025 has been official and has been confirmed by extensive audits. The Genome and Diagnostics Centre of GATC Biotech in Constance meets essential requirements for the competence of analysis and calibration laboratories such as DIN EN ISO/IEC 17025, DIN EN ISO 9001 and all further conditions. The compliance of standards is monitored by the DAkkS regularly.
GATC´s subsidiary LifeCodexx emphasizes the development of clinically validated molecular diagnostic tests and offers a risk-free alternative to common invasive examination methods such as amniocentesis.
GATC Biotech AG